key: cord-0892986-89ic6lmt
authors: Tereshchenko, L. G.; Bishop, A.; Fisher-Campbell, N.; Levene, J.; Morris, C.; Patel, H.; Beeson, E.; Blank, J.; Bradner, J. G.; Coblens, M.; Corpron, J.; Davison, J.; Denny, K.; Earp, M.; Florea, S.; Freeman, H.; Fuson, O.; Guillot, F.; Haq, K.; Hyde, J.; Khader, A.; Kolseth, C.; Kim, M.; Krol, O.; Lin, L.; Litwin, L.; Malik, A.; Mitchell, E.; Mohapatra, A.; Mullen, C.; Nix, C.; Oyeyemi, A.; Rutlen, C.; Corley-Stampke, L.; Tam, A.; Van Buren, I.; Wallace, J.; Khan, A.
title: Risk of Cardiovascular Events after Covid-19: a double-cohort study
date: 2021-12-29
journal: nan
DOI: 10.1101/2021.12.27.21268448
sha: 747dbd82d21785ab9911f13e26f52cb82fd0015e
doc_id: 892986
cord_uid: 89ic6lmt

Objective: To determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular events and all-cause mortality. Methods: We conducted a retrospective double-cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection [COVID-19(+) cohort] and its documented absence [COVID-19(-) cohort]. The study investigators drew a simple random sample of records from all Oregon Health & Science University (OHSU) Healthcare patients (N=65,585) with available COVID-19 test results, performed 03.01.2020 - 09.13.2020. Exclusion criteria were age < 18y and no established OHSU care. The primary outcome was a composite of cardiovascular morbidity and mortality. All-cause mortality was the secondary outcome. Results: The study population included 1355 patients (mean age 48.7 {+/-} 20.5 y; 770(57%) female, 977(72%) white non-Hispanic; 1072(79%) insured; 563(42%) with cardiovascular disease (CVD) history). During a median 6 months at risk, the primary composite outcome was observed in 38/319 (12%) COVID-19(+) and 65/1036 (6%) COVID-19(-) patients (p=0.001). In Cox regression adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk of the primary composite outcome (HR 1.71; 95%CI 1.06-2.78; p=0.029). Inverse-probability-weighted estimation, conditioned for 31 covariates, showed that for every COVID-19(+) patient, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19(-): average treatment effect on the treated -65.5 (95%CI -125.4 to -5.61) days; p=0.032. Conclusions: Either symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes and has a causal effect on all-cause mortality in a late post-COVID-19 period.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) uses angiotensinconverting enzyme 2 (ACE2) as the receptor-binding domain.

[1] Cardiac myocytes express ACE2, which makes the heart a target organ in the novel coronavirus disease 2019 . [2] The COVID-19 pandemic has revealed heterogenous cardiovascular manifestations of infection, which likely contribute to the high case fatality rate in COVID-19. [3] Myocardial injury in COVID-19 can be caused by both direct injury to cardiac myocytes as well as secondary effects from the systemic inflammation and hypercoagulable state seen in acute infection. Cardiovascular manifestations of COVID-19 include acute myocardial infarction, stress cardiomyopathy, myocarditis, heart failure (HF), pulmonary embolism, and cardiac arrhythmias. [3] Furthermore, COVID-19 patients with known cardiovascular disease (CVD) and other risk factors including age, hypertension, diabetes, obesity, kidney disease, and respiratory system disease are more likely to require critical care and have a higher mortality rate. [4] Post-acute or "long" COVID-19 has been described in patients with persistent symptoms or complications after the end of the acute phase of infection. [5, 6] The virulence and transmissibility of the SARS-CoV-2 virus and ongoing difficulties with public health policies and compliance challenges the ability to control COVID-19. As the virus mutates, it continues circulating throughout the globe. [7] Acute COVID-19 cardiovascular manifestations have been described in great depth. [8, 9, 10] However, the impact of COVID-19 on long-term cardiovascular outcomes remains unknown. [10] Furthermore, previous studies have had limitations, such as selection bias and absence of a control. Thus, it is essential to study the incidence, manifestations, and risk factors of post-acute outcomes that either symptomatic or asymptomatic SARS-CoV-2 infection poses on cardiovascular health. The first COVID-19(+) episode or a single COVID-19 (+) episode was defined as a positive SARS-CoV-2 test. For the data collection purpose, we assumed a 30-day length for one COVID-19(+) episode. If there were multiple PCR tests, negative PCR tests within the previous 13 days were permitted before the first COVID-19(+) episode.

All of the following conditions were required for a second COVID-19(+) episode after the first COVID-19(+) episode: (1) must be confirmed by PCR and not an antibody test; (2) occurred All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The study timeline is shown in Figure 1 . Study outcomes occurred at any time on or after the first day of the first COVID-19 episode, either (+) or (-). If there were two COVID-19 episodes, the 1 st set of outcomes occurred before the 1 st day of the second COVID-19 episode, and 2 nd set of outcomes occurred on or after the first day of the 2 nd COVID-19 episode. If neither a primary nor secondary outcome occurred, such record was censored on the last date the patient was known to be alive and event-free, which per the study design was the date when the study investigator collected EMR data.

The primary outcome was defined as a composite of cardiovascular death, acute HF, acute coronary syndrome (STEMI, NSTEMI, or unstable angina), incident stroke or transient ischemic   attack, another acute or new cardiovascular outcome prompting healthcare utilization (deep   venous thrombosis, pulmonary embolism, pulmonary hypertension, myocarditis, endocarditis, hypertension emergency, or kidney injury [15] ), critical care utilization (ICU bed) due to either primary or secondary cardiovascular condition, or development of a life-threatening arrhythmia submitted for review by the study investigators. In addition, the MMCC reviewed and adjudicated outcomes in seven randomly selected patient records and confirmed 100% agreement with the adjudication of outcomes performed by the study investigators.

We collected information on patient demographic characteristics, past medical history and medications, COVID-19 symptoms and treatment, ECG, and echocardiogram measurements, in accordance with the definitions and timeline of COVID-19 episodes. A data dictionary codebook is provided as a Supplement.

Healthy status was documented by regular annual check-ups and an absence of any medical history documented in the EMR. Cardiovascular disease history included at least one of the following: history of hypertension, supraventricular tachycardia (SVT; defined as either atrial fibrillation (AF), flutter, or unspecified SVT), VT/VF, SCA, HF, coronary heart disease (CHD; All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Respiratory disease history included a history of asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, obesity hypoventilation syndrome, sleep apnea, atelectasis, pneumonia, interstitial lung disease, home oxygen use, active or treated tuberculosis, treated or untreated latent tuberculosis infection (LTBI), non-tuberculosis mycobacterium infection or colonization, pneumoconiosis, invasive pulmonary fungal infection, any pulmonary hypertension, or cystic fibrosis. Liver disease history included a history of hepatitis, cirrhosis, hepatocellular carcinoma, metastatic liver cancer, alcoholic liver disease, toxic liver disease, All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Data were abstracted from the EMRs by the study investigators. Two investigators (HP and AM) reviewed a random subset of 15 EMR records and confirmed 100% inter-investigator agreement in the definition of exposure, outcomes, and covariates.

Normally distributed continuous variables were summarized as means and standard deviation (SD) and compared using a two-sided t-test. Pearson's χ 2 test was used to compare categorical All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint variables in patients with two levels of COVID-19 exposure: positive (COVID-19(+) cohort) and negative (COVID-19(-) cohort). COVID-19(+) cohort included patients with COVID-19(+) episodes (either 1 st or 2 nd , or both). COVID-19(-) cohort included patients who had COVID-19(-) episodes only and did not have any COVID-19(+) episodes. The analytical approach is illustrated in Figure 1 . The unadjusted Kaplan-Meier survivor functions were plotted for two levels of exposure for the primary and secondary outcomes. We used the log-rank test for the equality of survivor functions across two levels of exposure. Incidence rate and incidence rate difference were calculated to assess the absolute risk and absolute risk difference between two levels of exposure.

To answer a question of whether either asymptomatic or symptomatic SARS-CoV-2 infection is associated with outcomes independently from known COVID-19 risk factors, prevalent CVD, and cardiovascular risk factors, we constructed two Cox proportional hazards models. The proportional-hazards assumption was tested using stcox PH-assumptions suite of tests implemented in STATA (StataCorp LP, College Station, TX). Model 1 was adjusted for demographic (age, sex, and race-ethnicity group categories, defined as white non-Hispanic versus non-white or Hispanic) and socioeconomic characteristics (insurance status), and reason for testing (presence or absence of COVID-19 symptoms during the COVID-19 episode). Model 2, in addition to covariates included in model 1, was adjusted for cardiovascular and COVID-19 risk factors (history of CVD, cerebrovascular, liver disease, diabetes mellitus, conditions with an elevated risk of thromboembolism, immunocompromised status, and use of any prescription medication).

In addition, we utilized the causal inference approach and counterfactual analytical framework to investigate the hypothetically causal average treatment effect on the treated All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We used inverse-probability-weighted (IPW) estimators, using weighted averages of the observed outcome to calculate the potential-outcome means (POMs) and ATET. The IPW estimators were implemented in a three-step approach. First, we estimated the parameters of a treatment-assignment model (predicting probabilities of a subject to be included in a COVID-19(+) or COVID-19(-) cohort) and computed the component of the estimated weights that accounts for data missing because each subject was only observed after receiving one of the possible treatment levels, either COVID-19(+) or COVID-19(-). The model was conditioned for 31 covariates, including demographic and socioeconomic characteristics (age, sex, race, and ethnicity, health insurance status), the reason for COVID-19 testing, medical history of CVD, cerebrovascular, respiratory, kidney, liver, blood, systemic, endocrine disease, diabetes mellitus, addiction, conditions with immunocompromised and thromboembolic risk, use of prescription medications (including RAAS-blocking drugs, AV-nodal agents, antiplatelet or anticoagulant, and immunosuppressants), and the presence and type of COVID-19 symptoms (fever, fatigue, runny nose, headache, muscle and body aches, cough, shortness of breath, ageusia or anosmia, All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint and nausea). Next, we estimated the parameters of a time-to-censoring model and computed the component of estimated weights that accounts for data lost to censoring. In this retrospective study, the censoring time was determined by a random day when a study investigator collected EMR data unless a patient utilized healthcare and experienced potential outcome. Thus, we assumed that the time to censoring was random. We conditioned the model predicting time-tocensoring for the same 31 covariates as described above for the model predicting treatment assignment. At the final third step, we used both estimated weights to compute weighted averages of the outcomes for the COVID-19(+) cohort.

We conducted balance checks for the treatment-assignment model. We tested an overlap assumption that each study participant has a sufficient positive probability of being assigned to each treatment level. These checks depend only on the estimated probabilities of COVID-19(+) cohort assignment and are not affected by the censoring of the outcome. We observed (Supplemental Table 1 ) that the weighted standardized differences are much closer to 0 than the raw standardized differences, and the weighted variance ratios are much closer to 1 than the raw variance ratios. Therefore, we concluded that the model-based treatment weights balanced the covariates. We conducted a formal test of the hypothesis that the weighted constructed from the treatment-assignment model balances the covariates. We observed that we do not reject the null hypothesis that the treatment-assignment model is well specified (p=0.965; Figure 2 ). Thus, we used this model to look for evidence that the overlap condition is violated. Figure 2 showed that the densities for the probability to be included in the COVID-19(+) cohort were evenly distributed and showed sufficient overlap, and the maximum probability to be included in either COVID-19(+) or COVID-19(-) cohort was sufficiently less than 1. However, the densities for the probability to be included in the Covid19(-) cohort violated the overlap assumption, indicating All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint that there were unmeasured patients' characteristics that increased the probability for a patient to belong to COVID-19(-) cohort, likely because many of these patients underwent unrelated to COVID-19 medical procedures, and were tested for COVID-19 as a part of hospital precautions. Therefore, we reported only ATET estimators and not ATE estimators.

Statistical analyses were performed using STATA MP 17 (StataCorp LP, College Station, TX). A p-value < 0.05 was considered statistically significant. STATA do files are available at https://github.com/Tereshchenkolab/statistics.

Between March 1 st , 2020, and September 13 th , 2020, OHSU performed 99,711 COVID-19 tests for 65,585 individuals. The study investigators included a random sample of 1355 eligible OHSU patient records. Clinical characteristics of the patient population are presented in Table 1. COVID-19(+) patients were younger, more likely to be non-white or Hispanic, and less likely to be insured than COVID-19(-) patients. Furthermore, COVID-19(+) patients were more likely to have been prescribed medication and have a history of liver disease and/or diabetes mellitus (Table 1) . There was no difference in CVD history between the two exposure cohorts.

There was a significant difference in the reasons for COVID-19 testing between two cohorts: COVID-19(+) cohort (n=319) patients were twice as likely to be symptomatic than COVID-19(-) cohort (n=1036) patients ( Table 2 ). All COVID-19(+) episodes were confirmed by a PCR test, whereas 17 COVID-19(-) episodes (0.02%) were detected by an antibody test.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All known COVID-19 symptoms were more frequently observed in COVID-19(+) patients ( Table 2 ). The most frequent COVID-19 symptoms were cough and fever, observed in > 40% of patients. Runny nose, headache, muscle and body aches, and shortness of breath were present in > 20% of patients. Loss of taste (ageusia) or smell (anosmia) was present in approximately 17% of patients, and fatigue in approximately 16% of patients. Nausea, vomiting, diarrhea, anorexia, and chest pain were less frequent than other symptoms. In addition to the symptoms listed in Table 2 

During a median of 178 days at risk, the primary composite outcome was observed in a total of 103 patients, 38 (12%) of whom were from the COVID-19(+) cohort, and 65 (6%) were from COVID-19(-) cohort (p=0.001). Acute HF was diagnosed in 7, SCA/VF in 2, STEMI in 1, NSTEMI in 5, incident stroke in 5, endocarditis in 3, DVT/pulmonary embolism in 6, acute kidney dysfunction in 24, critical care utilization due to an acute primary or secondary cardiovascular condition in 25, and cardiovascular death in 25. Those who developed primary outcome were more likely to have greater severity of COVID-19 (Supplemental Table 2 ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Among COVID-19(+) cohort participants, the incidence rate of the primary outcome was higher (178.6 per 1,000 person-years of follow-up) than among COVID-19(-) cohort participants (149.2 per 1,000 person-years of follow-up). However, the incidence rate difference in the primary outcome between the two levels of exposure did not reach statistical significance (29.4; 95% CI from -38.04 to 96.8 per 1,000 person-years of follow-up; p=0.379).

In unadjusted survival analysis, COVID-19(+) patients had a significantly higher probability of developing the primary composite outcome than COVID-19(-) patients ( Figure 3 ). In unadjusted Cox regression analysis, COVID-19(+) exposure was associated with a more than 50% higher risk of the primary outcome (Table 3) . After adjustment for demographic characteristics, health insurance status, and reason for COVID-19 testing (model 1), COVID-19 infection remained associated with the primary outcome. However, the association attenuated after additional adjustment for prevalent CVD, cardiovascular, and COVID-19 risk factors in model 2. Proportional-hazards assumption was confirmed for all Cox regression models with the primary composite outcome.

In causal inference analysis (Table 4 ), in the COVID-19(+) cohort, the average time to the primary composite outcome was estimated to be 163.8 days or approximately 5.4 months more than when everyone in the COVID-19(+) cohort was COVID-19(-). The estimated average time All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In Kaplan-Meier survival analysis, there were no differences in all-cause mortality between COVID-19(-) and COVID-19(+) cohorts ( Figure 4 ). In unadjusted Cox regression analysis, COVID-19(+) exposure was associated with non-significant risk (Table 3) . Notably, the proportional-hazards assumption was violated for all Cox regression models with the all-cause death outcome.

Importantly, causal inference analysis using IPW estimators, conditioned for 31 covariates as described above, showed that for every COVID-19(+) patient, the average time to all-cause death was estimated to be 65.5 days less than when all these patients were COVID-19(-). The estimated average time to all-cause death when all these patients were COVID-19(-) was 98.6 days ( Table 4) .

Another pre-specified secondary outcome, documented cardiac arrhythmia, was recorded in only 10 study participants: 4 in the COVID-19(+) cohort and 9 in the COVID-19(-) cohort.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint Therefore, we did not conduct survival analyses due to a small number of documented cardiac arrhythmia outcomes.

In this retrospective double-cohort study, after rigorous adjustment for demographic and socioeconomic characteristics, reasons for COVID-19 testing, acute COVID-19 symptoms, (21%) prevalence of CMR abnormalities 6 months after moderate-to-severe COVID-19. [18] Furthermore, a well-matched case-control (n=75) 6-month post-COVID-19 CMR study All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Effects of COVID-19 (C-MORE) [21] showed that more than half of the patients experienced symptoms at 6 months post-COVID-19, limiting their ability to exercise. C-MORE investigators also noted a dissociation between symptoms and objective measures of cardiovascular health. [21] Our study did not ascertain the duration of the COVID-19 symptoms, [22] which should be further studied in future prospective studies.

Our study contributed to the growing body of knowledge showing the cardiovascular implications of SARS-CoV-2 infection regardless of its symptoms. Consistently with our findings, a large study of the English National Immunisation (NIMS) Database of COVID-19 vaccination, using self-controlled case series methodology, showed that SARS-CoV-2 infection was associated with a substantial increase in the risk of hospitalization or death from myocarditis, pericarditis, and cardiac arrhythmia. [23] The distinct mechanism of SARS-CoV-2 infection includes ACE2 downregulation, diminishing the protective, anti-inflammatory role of ACE2, and, thus, facilitating myocardial injury and fibrosis as the virus's long-term sequelae.

[24] All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We observed a low reinfection rate, consistent with other studies. [29] We found that COVID-19(+) patients were more likely to be non-white or Hispanic and less likely to be insured than COVID-19(-) patients. Furthermore, other studies have shown that All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint racial and ethnic minority groups have a significantly higher risk of COVID-19 positivity and that socioeconomic determinants were strongly associated with outcomes. [30] [27, 28] This recurrent disproportionality suggests that health inequities and socioeconomic determinants play a significant role in the ongoing COVID-19 pandemic and that interventions should be aimed at mitigating these negative impacts.

Important limitations of the study need to be considered. As in any retrospective cohort study, investigators had no control over the quality and completeness of the available EMR data.

The likelihood of unobserved and unmeasured confounding cannot be eliminated entirely, as an observational study is susceptible to confounding bias. Two cohorts assembled from the different COVDI-19(+) and COVID-19(-) populations may differ in multiple important ways that influenced the outcomes. We cannot completely rule out the violation of the conditional independence assumption. In our observational study, the treatment (SARS-CoV-2 infection exposure) was not randomly assigned so potential outcomes are not independent of the exposure.

We assumed that after conditioning on the covariates, the treatment assignment was as good as random. Nevertheless, we cannot be 100% sure that we observed, measured, and conditioned on enough covariates. We also note that the study was conducted in a single healthcare system.

Validation of the study findings in alternative populations will increase the chances that the observed association is causal.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Rx=prescribed.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

participants. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268448 doi: medRxiv preprint

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

A White Paper by the JAHA Editors

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Post-acute COVID-19 syndrome

Persistent Symptoms in Patients After Acute COVID-19

incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews

Cardiovascular procedural deferral and outcomes over COVID-19 pandemic phases: A multi-center study

Disease-Specific Excess Mortality During the COVID-19

Pandemic: An Analysis of Weekly US Death Data for 2020

Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic

The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemic. medRxiv : the preprint server for health sciences

Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study

Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review

Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity

Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers

Progressive left and right heart dysfunction in coronavirus disease-19: Prospective echocardiographic evaluation

Symptom Persistence Despite Improvement in Cardiopulmonary Health -Insights from longitudinal CMR, CPET and lung function testing post-COVID-19

COVID: long-term effects?

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Late Cardiac Pathology in

Severe Covid-19. A Postmortem Series of 30 Patients. Frontiers in Cardiovascular Medicine

Seasonal Influenza Infections and Cardiovascular Disease Mortality

Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic : A review

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-analysis

We would like to thank the following study investigators for their help with data collection:Hannah Kim, Isabelle Nguyen, Linh Nhat Taylor, Brianna Pickering, Maya Herzig, Olivia Glatt, Tahmina Karimyar, and Timothy Kang.